Stivarga 40mg

Stivarga 40mg contains regorafenib, an oral targeted anticancer medication used to treat certain types of cancer. It belongs to a class of medicines called multikinase inhibitors, which block the activity of specific proteins involved in cancer cell growth, tumor blood vessel formation, and the development of cancer.

Regorafenib inhibits several protein kinases, including those involved in tumor cell signaling and angiogenesis, the process through which tumors develop new blood vessels. By interfering with these pathways, it can help slow the growth and progression of certain cancers.

Stivarga is approved for specific patients with metastatic colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma (HCC), a type of liver cancer. The appropriate indication depends on the patient’s previous treatments, cancer characteristics, and overall medical condition.

This medication is available as an oral tablet containing 40mg of regorafenib. It is a prescription medicine that must be used under the supervision of an experienced oncology specialist.

How Does Stivarga 40mg Tablet Work?

Stivarga 40mg is an oral targeted cancer medication that contains regorafenib. It works by inhibiting multiple protein kinases that contribute to cancer cell growth, tumor development, and the formation of blood vessels that supply tumors with oxygen and nutrients.

Regorafenib blocks the activity of several kinases involved in tumor angiogenesis, including VEGFR-related pathways, as well as proteins associated with cancer cell signaling. This action may restrict the blood supply that supports tumor growth and interfere with signals that help cancer cells survive and multiply.

By targeting these pathways, Stivarga may help slow disease progression in eligible patients with certain advanced cancers. However, its effectiveness varies depending on the cancer type, previous treatment, and individual response.

Stivarga is classified as a multikinase inhibitor. Its use, dosage, and treatment duration must be determined by an oncologist, who will consider the patient’s medical history, liver function, other medications, and tolerance to treatment.

Dosage of Stivarga 40mg Tablets :

Stivarga 40mg contains regorafenib and is prescribed for specific cancers, including metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma, according to the approved treatment indication. The dosage must be followed exactly as directed by the treating oncologist.

The usual recommended starting dose for adults is 160mg once daily, equivalent to four 40mg tablets, for the first 21 days of each 28-day treatment cycle. Treatment is generally followed by a seven-day break. The prescribed dose may differ if adjustments are required because of side effects or other clinical factors.

Stivarga tablets are generally taken at the same time each day with a low-fat meal. They should be swallowed whole with water. Patients should follow the specific administration instructions provided by their healthcare professional.

The oncologist may reduce the dose, temporarily interrupt treatment, or discontinue therapy depending on side effects, liver function, and treatment response. Blood pressure, liver function, and other relevant health parameters should be monitored regularly. Do not change the dosage or treatment schedule without medical advice.

Benefits of Using Stivarga 40mg Tablets :

Stivarga 40mg is a targeted anticancer medicine used to manage certain advanced cancers when treatment with other therapies has been unsuccessful or is no longer suitable. Its benefits depend on the cancer type, previous treatment, and individual clinical circumstances.

• Metastatic colorectal cancer: Regorafenib may help slow disease progression in eligible adults whose cancer has progressed following specified standard treatments.
• Gastrointestinal stromal tumors (GIST): It may be prescribed for adults with advanced GIST that cannot be removed surgically or has spread, following previous treatment with imatinib and sunitinib.
• Hepatocellular carcinoma (HCC): It may be used for adults with liver cancer who have previously received sorafenib and meet the relevant treatment criteria.
• Targeted anticancer action: Regorafenib inhibits several kinases involved in tumor growth, blood vessel formation, and cancer cell signaling.
• Oral administration: The tablet formulation allows patients to take the medication at home according to their prescribed treatment schedule, with appropriate specialist monitoring.

Stivarga does not cure every cancer or produce the same response in all patients. Treatment decisions should be based on the approved indication, previous therapies, and an oncologist’s assessment of potential benefits and risks.

Side Effects of Stivarga 40mg Tablets :

Treatment with Stivarga may cause side effects ranging from mild to serious. Their severity varies according to the individual patient’s health, dosage, and response to treatment. Commonly reported side effects include:

• Fatigue and weakness
• Diarrhea
• Reduced appetite and weight loss
• Hand-foot skin reaction, which may cause redness, tenderness, pain, or blistering on the palms and soles
• High blood pressure
• Mouth sores and inflammation
• Abdominal pain and nausea
• Changes in voice
• Fever or infection

Regorafenib can also cause serious complications, including severe liver injury, significant bleeding, gastrointestinal perforation, impaired wound healing, and rare cases of a serious brain-related condition called posterior reversible encephalopathy syndrome (PRES).

Seek urgent medical attention if you experience yellowing of the skin or eyes, dark urine, severe abdominal pain, significant bleeding, chest pain, severe headache, confusion, seizures, or sudden changes in vision. Contact your healthcare professional promptly if side effects become persistent or difficult to manage.

Liver function and blood pressure should be assessed before and during treatment. Your doctor may also recommend additional tests and dose adjustments to reduce the risk of complications. Take Stivarga only as prescribed and report new or worsening symptoms to your oncology team.

Conclusion :

Stivarga 40mg is a prescription anticancer medicine containing regorafenib, a multikinase inhibitor used to treat certain patients with metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. Treatment suitability, dosage, and duration depend on the cancer type, previous therapies, and individual health factors. Specialist supervision and regular monitoring are essential to assess treatment response and manage potential side effects.

Important Medical Warning :

Use Stivarga 40mg strictly according to your doctor’s prescription. Follow your healthcare professional’s instructions regarding dosage, administration, and treatment duration. Do not self-medicate, alter the prescribed dose, or discontinue treatment without consulting your doctor. Inform your healthcare team about all medications and supplements you take, as well as any existing liver problems or other medical conditions. This medication requires specialist supervision and appropriate monitoring throughout treatment.